Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Vanguard Short Term Corporate Bond ETF (VCSH) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Vanguard Short Term Corporate Bond ETFTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Vanguard Short Term Corporate Bond ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.61 (market cap $9.43B), while Vanguard Short Term Corporate Bond ETF trades at $78.6. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Vanguard Short Term Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.

BIOVCSH
Market Cap
$9.43B
Sector
HealthFixed Income
52-Week High
$356.25$80.20
52-Week Low
$241.71$78.41
Enterprise Value
$9.18B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.

BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.

Vanguard Short Term Corporate Bond ETF

VCSH trades at $78.615, up 0.16% with a bearish technical outlook as moving averages signal selling pressure while oscillators remain neutral. The ETF maintains a 4.77% yield with short 2.7-year duration, though recent analysis suggests limited upside due to tight credit spreads. Recent institutional activity shows mixed positioning with Apella Capital reducing holdings while Bessemer Group and Allspring increased stakes significantly.

The outlook remains cautious with downgrades to 'Hold' citing unattractive entry points, though the short duration provides downside protection. Key risks include credit spread widening and Fed policy uncertainty, while the primary opportunity lies in stable income generation for conservative investors seeking corporate bond exposure.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Vanguard Short Term Corporate Bond ETF

VCSH tracks the Bloomberg U.S. 1-5 Year Corporate Bond Index, focusing on high-quality, investment-grade debt with short maturities. It is designed to offer higher income than Treasury bills with significantly lower interest rate sensitivity than intermediate or long-term bond funds.

Read more on VCSH